A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)
Sponsor: Daiichi Sankyo
This observational or N/A phase trial investigates Prostate Cancer and Prostatic Neoplasms and is currently actively recruiting participants. Daiichi Sankyo leads this study, which shows 10 recorded versions since 2025 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
May 4, 2026 — Present [daily]
Recruiting
Phase: PHASE3 → None
-
Mar 2026 — May 2026 [monthly]
Recruiting PHASE3
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE3
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE3
-
Nov 2025 — Jan 2026 [monthly]
Recruiting PHASE3
▶ Show 5 earlier versions
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE3
-
Jul 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
May 2025 — Jun 2025 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer overall and live longer without the cancer growing or spreading than people who receive chemotherapy.
Contact Information
- Daiichi Sankyo
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .